RESUMO
BACKGROUND: In response to the 2022 mpox outbreak in the United States, people with higher potential for exposure to mpox were recommended to receive 2 doses of the JYNNEOS vaccine. Vaccine safety was monitored using 2 complementary systems. METHODS: The Vaccine Adverse Event Reporting System (VAERS) is a passive surveillance system that accepts reports of adverse events after vaccination. VAERS is capable of rapidly identifying rare adverse events and unusual reporting patterns. Medical records were requested and reviewed for adverse events of special interest, including myocarditis. Adverse event reporting rates were calculated as the number of verified adverse event cases divided by the number of JYNNEOS doses administered. V-safe for mpox was a voluntary smartphone-based vaccine safety surveillance system that sent enrolled persons text messages linked to health surveys asking about reactions and health impact events occurring after vaccination. RESULTS: There were 1,207,056 JYNNEOS doses administered in the United States. VAERS received 1927 reports for JYNNEOS. The myocarditis reporting rate per million doses was 2.69 after dose 1 and 8.64 after dose 2. V-safe had 213 participants complete at least one health survey. Rates of injection site and systemic reactions were similar in the first week after dose 1 and dose 2. CONCLUSIONS: JYNNEOS vaccine safety surveillance findings from VAERS and v-safe did not identify any unexpected safety concerns. The VAERS reporting rate for myocarditis was similar to previously published population background rates.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos , Surtos de Doenças , Mpox , Vacina Antivariólica , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Sistemas de Notificação de Reações Adversas a Medicamentos/estatística & dados numéricos , Surtos de Doenças/prevenção & controle , Miocardite/epidemiologia , Miocardite/induzido quimicamente , Smartphone , Envio de Mensagens de Texto , Estados Unidos/epidemiologia , Vacinação/efeitos adversos , Vacina Antivariólica/administração & dosagem , Vacina Antivariólica/efeitos adversos , Mpox/prevenção & controleAssuntos
Infecções por Vírus Respiratório Sincicial , Vacinas contra Vírus Sincicial Respiratório , Humanos , Estados Unidos/epidemiologia , Idoso , Vacinas contra Vírus Sincicial Respiratório/administração & dosagem , Pessoa de Meia-Idade , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Infecções por Vírus Respiratório Sincicial/epidemiologia , Feminino , Masculino , Idoso de 80 Anos ou mais , Sistemas de Notificação de Reações Adversas a MedicamentosRESUMO
BACKGROUND: Pregnant persons are at increased risk of severe COVID-19 illness. Bivalent mRNA COVID-19 vaccination is recommended for everyone, including pregnant persons. However, data are limited on the safety of bivalent mRNA COVID-19 vaccination during pregnancy. OBJECTIVE: To evaluate and summarize reports to the Vaccine Adverse Event Reporting System (VAERS), a national spontaneous reporting system, among pregnant persons who received bivalent mRNA COVID-19 vaccine. METHODS: VAERS U.S. reports of adverse events (AEs) in pregnant persons who received the bivalent mRNA COVID-19 vaccine from 9/1/2022-03/31/2023 were identified. Clinicians reviewed all reports and available medical records. AEs of these reports were compared with AEs reported to VAERS following monovalent mRNA COVID-19 booster vaccination in pregnancy. RESULTS: VAERS received 136 reports for pregnant persons who received bivalent mRNA COVID-19 vaccine; 87 (64 %) after BNT162b2 (Pfizer-BioNTech), and 48 (35 %) after mRNA-1273 (Moderna); 28 (20.6 %) reports were classified as serious. The most common pregnancy-specific outcomes reported included 12 (8.8 %) spontaneous abortions (<20 weeks gestation), 6 (4.4 %) episodes of preterm delivery, and 5 (3.7 %) reports of preeclampsia. One stillbirth (≥20 weeks gestation) was reported. No maternal or infant deaths were reported. There were 6 reports of AEs in infants, which included 3 reports of admissions to the neonatal intensive care unit: two infants with low birth weight, and one infant with a patent ductus arteriosus and patent foramen ovale. Non-pregnancy-specific adverse events were mostly COVID-19 infection and systemic reactions (e.g., headache, fatigue). Pregnancy-specific conditions were reported less frequently after bivalent mRNA COVID-19 vaccination compared to monovalent mRNA COVID-19 booster vaccination (3rd and 4th dose). CONCLUSIONS: Based on this review of reports to VAERS, the safety profile of bivalent mRNA COVID-19 vaccination in pregnant persons was comparable to that observed for monovalent mRNA COVID-19 booster vaccination (3rd and 4th dose) in pregnant persons.
Assuntos
COVID-19 , Vacinas , Feminino , Humanos , Recém-Nascido , Gravidez , Sistemas de Notificação de Reações Adversas a Medicamentos , Vacina BNT162 , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Estados Unidos/epidemiologiaRESUMO
We identified U.S. reports of postmenopausal bleeding in the VAERS (Vaccine Adverse Event Reporting System) between December 13, 2020, and December 13, 2021. Among 711,224 VAERS reports after coronavirus disease 2019 (COVID-19) vaccination, during our study period, we identified 554 presumptive postmenopausal bleeding reports; 434 were further classified as verified based on data abstracted from reports and medical records, when available. In the United States, by December 14, 2021, 58.8 million women aged 50 years or older had received at least one dose of a COVID-19 vaccine, corresponding to approximately seven verified VAERS postmenopausal bleeding reports per 1 million women aged 50 years or older who received a COVID-19 vaccine. Reports of postmenopausal bleeding after COVID-19 vaccination in VAERS were rare, and causes of postmenopausal bleeding based on medical record review were consistent with known causes of postmenopausal bleeding.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos , Vacinas contra COVID-19 , COVID-19 , Pós-Menopausa , Hemorragia Uterina , Humanos , Feminino , Pessoa de Meia-Idade , Vacinas contra COVID-19/efeitos adversos , Idoso , Hemorragia Uterina/etiologia , Hemorragia Uterina/induzido quimicamente , COVID-19/prevenção & controle , COVID-19/epidemiologia , Sistemas de Notificação de Reações Adversas a Medicamentos/estatística & dados numéricos , Estados Unidos/epidemiologia , SARS-CoV-2 , Vacinação/efeitos adversosRESUMO
The GSK and Pfizer respiratory syncytial virus (RSV) vaccines are both indicated for adults aged 60 years and older, but only the Pfizer product is approved for use in pregnancy to prevent RSV-associated lower respiratory tract disease in infants aged younger than 6 months. To assess for vaccine administration errors (ie, administration of the GSK RSV vaccine to pregnant persons) VAERS (Vaccine Adverse Event Reporting System), a U.S. passive reporting system, was searched for the time period from August 2023 to January 2024. A total of 113 reports of these administration errors were identified. Most reports (103, 91.2%) did not describe an adverse event. These administration errors are preventable with proper education and training and other preventive measures.
Assuntos
Infecções por Vírus Respiratório Sincicial , Vacinas contra Vírus Sincicial Respiratório , Adulto , Feminino , Humanos , Gravidez , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Infecções por Vírus Respiratório Sincicial/induzido quimicamente , Vacinas contra Vírus Sincicial Respiratório/efeitos adversos , Vacinação , Erros MédicosRESUMO
INTRODUCTION: Bivalent mRNA coronavirus disease 2019 (COVID-19) vaccines may be simultaneously administered with other recommended vaccines, including seasonal influenza vaccines. However, few studies have evaluated the safety of co-administration of bivalent mRNA COVID-19 and seasonal influenza vaccines. OBJECTIVE: The aim was to describe reports to the Vaccine Adverse Event Reporting System (VAERS) after co-administration of bivalent mRNA COVID-19 and seasonal influenza vaccines. METHODS: We searched the VAERS database for reports of adverse events (AEs) following co-administration of bivalent mRNA COVID-19 and seasonal influenza vaccines during the period of September 1, 2022-March 31, 2023. We assessed the characteristics of these reports and described the most frequently reported AEs. Clinicians reviewed available medical records for reports of serious AEs and adverse events of special interest (AESI). RESULTS: During the period of 1 September 2022 through 31 March 2023, VAERS received 3689 reports of AEs following co-administration of bivalent mRNA COVID-19 and seasonal influenza vaccines. The median age of vaccinees was 59 years (interquartile range 39, 70 years); 342 reports (9.3%) were classified as serious. The most common AEs among non-serious reports were severe-acute-respiratory-syndrome-related coronavirus (SARS-CoV-2) infection (785, 23.5%), cough (592, 17.7%), and fatigue (568, 17.0%). The most common AEs among serious reports were Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection (88, 25.7%), dyspnea (81, 23.7%), and condition aggravated (55, 16.1%). DISCUSSION: Reports of AEs following co-administration of bivalent mRNA COVID-19 and seasonal influenza vaccines did not reveal any unusual or unexpected patterns of AEs. Increased reporting of certain events (e.g., COVID-19) was expected due to Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) reporting requirements. CDC and FDA will continue to monitor the safety of co-administration of mRNA COVID-19 and seasonal influenza vaccines.
Assuntos
COVID-19 , Vacinas contra Influenza , Humanos , Sistemas de Notificação de Reações Adversas a Medicamentos , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Vacinas contra Influenza/efeitos adversos , RNA Mensageiro , SARS-CoV-2 , Estados Unidos , Adulto , Pessoa de Meia-Idade , IdosoAssuntos
Acidentes de Trabalho , Eliminação de Resíduos , Países em Desenvolvimento , Primeiros Socorros , Inquéritos e Questionários , População Urbana , Ferimentos Penetrantes Produzidos por Agulha , Gerenciamento de Resíduos , Patógenos Transmitidos pelo Sangue , Resíduos Perigosos , México , Agulhas , SeringasAssuntos
Humanos , Acidentes de Trabalho/estatística & dados numéricos , Ferimentos Penetrantes Produzidos por Agulha/epidemiologia , Eliminação de Resíduos , Gerenciamento de Resíduos , Patógenos Transmitidos pelo Sangue , Países em Desenvolvimento , Primeiros Socorros , Resíduos Perigosos , México/epidemiologia , Agulhas , Inquéritos e Questionários , Seringas , População UrbanaRESUMO
El presente estudio describe las características clínicas, diagnósticas y terapeúticas en cuatro pacientes con hidatidosis esplénica primaria tratados entre 1991 y 1993 en tres hospitales de la ciudad de Lima, donde con frecuencia se hospitalizan pacientes con esta parasitosis. El cuadro clínico no permitió llegar al diagnóstico correcto en los cuatro casos. En dos pacientes el diagnóstico fue un hallazgo accidental. La ecografía dió resultados errados o dudosos en tres pacientes. La Tomografía Axial Computarizada permitió precisar la localización del quiste esplénico en uno de estos casos. Un paciente presentó infección del quiste como complicación en la evolución de la enfermedad antes del acto quirúrgico. En todos los pacientes se realizó esplenectomía total sin complicaciones. La hidatidosis esplénica es infrecuente, pero debe ser considerada en aquellos pacientes con quiste en otra localización o en aquellos que presenten imágenes sugestivas de esta patología